<H1>Chapter DOI: 10.1007/978-1-60327-829-4_4<br/>Cited-By Count: 0</H1><table border="1" width="30%"><tr><td>Total References</td><td>50</td></tr><tr><td>Springer references</td><td>2</td></tr><tr><td>Non Springer references</td><td>48</td></tr><tr><td>BibStructured Count</td><td width="10%">50</td></tr><tr><td>BibUnstructured Count</td><td width="10%">0</td></tr><tr><td>DOI already available in SpringerLink</td><td>45</td></tr><tr><td>Additional DOI extracted from CrossRef-Meta</td><td>1</td></tr><tr><td>Additional DOI extracted from CrossRef-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from ResearchGate-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from SpringerLink-FUZZY-Search</td><td>0</td></tr><tr><td>Spelling Mistakes</td><td>NULL</td></tr><tr><td>Wrong DOI</td><td>0</td></tr><tr><td>ISBN</td><td>NULL</td></tr><tr><td>Web Link</td><td>NULL</td></tr><tr><td>DOI Obtained For Springer Published</td><td>1</td></tr><tr><td>DOI Obtained For Non Springer</td><td>0</td></tr><tr><td>DOI Obtained From Structured Ref</td><td>1</td></tr><tr><td>DOI Obtained From Unstructured Ref</td><td>0</td></tr><tr><td>Valid DOI Enriched</td><td>0</td></tr></table></br></br><table border="1">
<tr><th>Bib. ID</th><th>Ref. Type</th><th>References</th><th>DOI</th><th>Suspected DOI</th><th>DOI Source</th><th>Validated Elements</th><th>Validation Source</th></tr><tr><td>CR1_4</td><td>BibArticle</td><td>Hsing AW, Chokkalingam AP. Prostate cancer epidemiology. Front Biosci 2006;11:1388&#8211;413.</td><td><a href=http://dx.doi.org/10.2741/1891>10.2741/1891</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR2_4</td><td>BibArticle</td><td>Chokkalingam AP, et al. Molecular epidemiology of prostate cancer: hormone-related genetic loci. Front Biosci 2007;12:3436&#8211;60.</td><td><a href=http://dx.doi.org/10.2741/2325>10.2741/2325</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR3_4</td><td>BibArticle</td><td>Freedman ML, et al. Admixture mapping identifies 8q24 as a prostate cancer risk locus in African-American men. Proc Natl Acad Sci U S A 2006;103(38):14068&#8211;73.</td><td><a href=http://dx.doi.org/10.1073/pnas.0605832103>10.1073/pnas.0605832103</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR4_4</td><td>BibArticle</td><td>Gudmundsson J, et al. Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet 2007;39(5):631&#8211;7.</td><td><a href=http://dx.doi.org/10.1038/ng1999>10.1038/ng1999</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR5_4</td><td>BibArticle</td><td>Haiman CA, et al. Multiple regions within 8q24 independently affect risk for prostate cancer. Nat Genet 2007;39(5):638&#8211;44.</td><td><a href=http://dx.doi.org/10.1038/ng2015>10.1038/ng2015</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR6_4</td><td>BibArticle</td><td>Suuriniemi M, et al. Confirmation of a positive association between prostate cancer risk and a locus at chromosome 8q24. Cancer Epidemiol Biomarkers Prev 2007;16(4):809&#8211;14.</td><td><a href=http://dx.doi.org/10.1158/1055-9965.EPI-06-1049>10.1158/1055-9965.EPI-06-1049</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR7_4</td><td>BibArticle</td><td>Witte JS. Multiple prostate cancer risk variants on 8q24. Nat Genet 2007;39(5):579&#8211;80.</td><td><a href=http://dx.doi.org/10.1038/ng0507-579>10.1038/ng0507-579</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR8_4</td><td>BibArticle</td><td>Yeager M, et al. Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet 2007;39(5):645&#8211;9.</td><td><a href=http://dx.doi.org/10.1038/ng2022>10.1038/ng2022</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR9_4</td><td>BibArticle</td><td>Zheng SL, et al. Association between two unlinked loci at 8q24 and prostate cancer risk among European Americans. J Natl Cancer Inst 2007;99(20):1525&#8211;33.</td><td><a href=http://dx.doi.org/10.1093/jnci/djm169>10.1093/jnci/djm169</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR10_4</td><td>BibArticle</td><td>Huggins C, Hodges CV. The effects of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941;1:293&#8211;7.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR11_4</td><td>BibArticle</td><td>Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA 2005;294(2):238&#8211;44.</td><td><a href=http://dx.doi.org/10.1001/jama.294.2.238>10.1001/jama.294.2.238</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR12_4</td><td>BibArticle</td><td>Chu LW, Reichardt JK, Hsing AW. Androgens and the molecular epidemiology of prostate cancer. Curr Opin Endocrinol Diabetes Obes 2008;15(3):261&#8211;70.</td><td><a href=http://dx.doi.org/10.1097/MED.0b013e3282febcf6>10.1097/MED.0b013e3282febcf6</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR13_4</td><td>BibArticle</td><td>Hsing AW, Reichardt JK, Stanczyk FZ. Hormones and prostate cancer: current perspectives and future directions. Prostate 2002;52(3):213&#8211;35.</td><td><a href=http://dx.doi.org/10.1002/pros.10108>10.1002/pros.10108</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR14_4</td><td>BibArticle</td><td>Platz EA, Giovannucci E. The epidemiology of sex steroid hormones and their signaling and metabolic pathways in the etiology of prostate cancer. J Steroid Biochem Mol Biol 2004;92(4):237&#8211;53.</td><td><a href=http://dx.doi.org/10.1016/j.jsbmb.2004.10.002>10.1016/j.jsbmb.2004.10.002</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR15_4</td><td>BibChapter</td><td>Stanczyk FZ, et al. Alterations in circulating levels of androgens and PSA during treatment with Fiansteride in men at high risk for prostate cancer. In: Li JJ, et al., editors. Hormonal carcinogenesis II. New York: Springer; 1996.</td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.1007/978-1-4612-2332-0>10.1007/978-1-4612-2332-0</a></td><td><b>CrossRef-Meta</b></td>
<td>BookTitle, Year</td><td>CrossRef</td></tr><tr><td>CR16_4</td><td>BibArticle</td><td>Travis RC, et al. Serum androgens and prostate cancer among 643 cases and 643 controls in the European prospective investigation into cancer and nutrition. Int J Cancer 2007;121(6):1331&#8211;8.</td><td><a href=http://dx.doi.org/10.1002/ijc.22814>10.1002/ijc.22814</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR17_4</td><td>BibArticle</td><td>Chamberlain NL, Driver ED, Miesfeld RL. The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucleic Acids Res 1994;22(15):3181&#8211;6.</td><td><a href=http://dx.doi.org/10.1093/nar/22.15.3181>10.1093/nar/22.15.3181</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR18_4</td><td>BibArticle</td><td>Richter E, Srivastava S, Dobi A. Androgen receptor and prostate cancer. Prostate Cancer Prostatic Dis 2007;10(2):114&#8211;8.</td><td><a href=http://dx.doi.org/10.1038/sj.pcan.4500936>10.1038/sj.pcan.4500936</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR19_4</td><td>BibArticle</td><td>Culig Z, et al. Hyperactive androgen receptor in prostate cancer: what does it mean for new therapy concepts? Histol Histopathol 1997;12(3):781&#8211;6.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR20_4</td><td>BibArticle</td><td>Hsing AW, et al. Polymorphic CAG/CAA repeat length in the AIB1/SRC-3 gene and prostate cancer risk: a population-based case-control study. Cancer Epidemiol Biomarkers Prev 2002;11(4):337&#8211;41.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR21_4</td><td>BibArticle</td><td>Rahman M, Miyamoto H, Chang C. Androgen receptor coregulators in prostate cancer: mechanisms and clinical implications. Clin Cancer Res 2004;10(7):2208&#8211;19.</td><td><a href=http://dx.doi.org/10.1158/1078-0432.CCR-0746-3>10.1158/1078-0432.CCR-0746-3</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR22_4</td><td>BibArticle</td><td>Roddam AW, et al. Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst 2008;100(3):170&#8211;83.</td><td><a href=http://dx.doi.org/10.1093/jnci/djm323>10.1093/jnci/djm323</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR23_4</td><td>BibArticle</td><td>Platz EA, et al. Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era. Cancer Epidemiol Biomarkers Prev 2005;14(5):1262&#8211;9.</td><td><a href=http://dx.doi.org/10.1158/1055-9965.EPI-04-0371>10.1158/1055-9965.EPI-04-0371</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR24_4</td><td>BibArticle</td><td>Weiss JM, et al. Endogenous sex hormones and the risk of prostate cancer: a prospective study. Int J Cancer 2008;122(10):2345&#8211;50.</td><td><a href=http://dx.doi.org/10.1002/ijc.23326>10.1002/ijc.23326</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR25_4</td><td>BibArticle</td><td>Hsing AW, Chu LW, Stanczyk FZ. Androgen and prostate cancer: is the hypothesis dead? Cancer Epidemiol Biomarkers Prev 2008;17(10):2525&#8211;30.</td><td><a href=http://dx.doi.org/10.1158/1055-9965.EPI-08-0448>10.1158/1055-9965.EPI-08-0448</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR26_4</td><td>BibArticle</td><td>Mulligan T, et al. Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract 2006;60(7):762&#8211;9.</td><td><a href=http://dx.doi.org/10.1111/j.1742-1241.2006.00992.x>10.1111/j.1742-1241.2006.00992.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR27_4</td><td>BibArticle</td><td>Tostain JL, Blanc F. Testosterone deficiency: a common, unrecognized syndrome. Nat Clin Pract Urol 2008;5(7):388&#8211;96.</td><td><a href=http://dx.doi.org/10.1038/ncpuro1167>10.1038/ncpuro1167</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR28_4</td><td>BibArticle</td><td>Carter HB, et al. Longitudinal evaluation of serum androgen levels in men with and without prostate cancer. Prostate 1995;27(1):25&#8211;31.</td><td><a href=http://dx.doi.org/10.1002/pros.2990270106>10.1002/pros.2990270106</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR29_4</td><td>BibArticle</td><td>Slater S, Oliver RT. Testosterone: its role in development of prostate cancer and potential risk from use as hormone replacement therapy. Drugs Aging 2000;17(6):431&#8211;9.</td><td><a href=http://dx.doi.org/10.2165/00002512-200017060-00001>10.2165/00002512-200017060-00001</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR30_4</td><td>BibArticle</td><td>Ross RK, et al. 5-Alpha-reductase activity and risk of prostate cancer among Japanese and US white and black males. Lancet 1992;339(8798):887&#8211;9.</td><td><a href=http://dx.doi.org/10.1016/0140-6736(92)90927-U>10.1016/0140-6736(92)90927-U</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR31_4</td><td>BibArticle</td><td>Wu AH, et al. Serum androgens and sex hormone-binding globulins in relation to lifestyle factors in older African-American, white, and Asian men in the United States and Canada. Cancer Epidemiol Biomarkers Prev 1995;4(7):735&#8211;41.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR32_4</td><td>BibArticle</td><td>Morgentaler A, Bruning 3rd CO, DeWolf WC. Occult prostate cancer in men with low serum testosterone levels. JAMA 1996;276(23):1904&#8211;6.</td><td><a href=http://dx.doi.org/10.1001/jama.1996.03540230054035>10.1001/jama.1996.03540230054035</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR33_4</td><td>BibArticle</td><td>Morgentaler A, Rhoden EL. Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/mL or less. Urology 2006;68(6):1263&#8211;7.</td><td><a href=http://dx.doi.org/10.1016/j.urology.2006.08.1058>10.1016/j.urology.2006.08.1058</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR34_4</td><td>BibArticle</td><td>Yamamoto S, et al. Preoperative serum testosterone level as an independent predictor of treatment failure following radical prostatectomy. Eur Urol 2007;52(3):696&#8211;701.</td><td><a href=http://dx.doi.org/10.1016/j.eururo.2007.03.052>10.1016/j.eururo.2007.03.052</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR35_4</td><td>BibArticle</td><td>Hoffman MA, DeWolf WC, Morgentaler A. Is low serum free testosterone a marker for high grade prostate cancer? J Urol 2000;163(3):824&#8211;7.</td><td><a href=http://dx.doi.org/10.1016/S0022-5347(05)67812-3>10.1016/S0022-5347(05)67812-3</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR36_4</td><td>BibArticle</td><td>Schatzl G, et al. High-grade prostate cancer is associated with low serum testosterone levels. Prostate 2001;47(1):52&#8211;8.</td><td><a href=http://dx.doi.org/10.1002/pros.1046>10.1002/pros.1046</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR37_4</td><td>BibArticle</td><td>Massengill JC, et al. Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy. J Urol 2003;169(5):1670&#8211;5.</td><td><a href=http://dx.doi.org/10.1097/01.ju.0000062674.43964.d0>10.1097/01.ju.0000062674.43964.d0</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR38_4</td><td>BibArticle</td><td>Ribeiro M, Ruff P, Falkson G. Low serum testosterone and a younger age predict for a poor outcome in metastatic prostate cancer. Am J Clin Oncol 1997;20(6):605&#8211;8.</td><td><a href=http://dx.doi.org/10.1097/00000421-199712000-00015>10.1097/00000421-199712000-00015</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR39_4</td><td>BibArticle</td><td>Sih R, et al. Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial. J Clin Endocrinol Metab 1997;82(6):1661&#8211;7.</td><td><a href=http://dx.doi.org/10.1210/jc.82.6.1661>10.1210/jc.82.6.1661</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR40_4</td><td>BibArticle</td><td>Svetec DA, et al. The effect of parenteral testosterone replacement on prostate specific antigen in hypogonadal men with erectile dysfunction. J Urol 1997;158(5):1775&#8211;7.</td><td><a href=http://dx.doi.org/10.1016/S0022-5347(01)64126-0>10.1016/S0022-5347(01)64126-0</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR41_4</td><td>BibArticle</td><td>Kenny AM, et al. Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels. J Gerontol A Biol Sci Med Sci 2001;56(5):M266&#8211;72.</td><td><a href=http://dx.doi.org/10.1093/gerona/56.5.M266>10.1093/gerona/56.5.M266</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR42_4</td><td>BibArticle</td><td>Snyder PJ, et al. Effects of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab 2000;85(8):2670&#8211;7.</td><td><a href=http://dx.doi.org/10.1210/jc.85.8.2670>10.1210/jc.85.8.2670</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR43_4</td><td>BibArticle</td><td>Rhoden EL, Morgentaler A. Testosterone replacement therapy in hypogonadal men at high risk for prostate cancer: results of 1 year of treatment in men with prostatic intraepithelial neoplasia. J Urol 2003;170(6 Pt 1):2348&#8211;51.</td><td><a href=http://dx.doi.org/10.1097/01.ju.0000091104.71869.8e>10.1097/01.ju.0000091104.71869.8e</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR44_4</td><td>BibArticle</td><td>Rhoden EL, Morgentaler A. Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med 2004;350(5):482&#8211;92.</td><td><a href=http://dx.doi.org/10.1056/NEJMra022251>10.1056/NEJMra022251</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR45_4</td><td>BibArticle</td><td>Makinen T, et al. Second round results of the Finnish population-based prostate cancer screening trial. Clin Cancer Res 2004;10(7):2231&#8211;6.</td><td><a href=http://dx.doi.org/10.1158/1078-0432.CCR-03-0338>10.1158/1078-0432.CCR-03-0338</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR46_4</td><td>BibArticle</td><td>Grober ED, et al. Correlation between simultaneous PSA and serum testosterone concentrations among eugonadal, untreated hypogonadal and hypogonadal men receiving testosterone replacement therapy. Int J Impot Res 2008;20(6):561&#8211;5.</td><td><a href=http://dx.doi.org/10.1038/ijir.2008.40>10.1038/ijir.2008.40</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR47_4</td><td>BibArticle</td><td>Marks LS, et al. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA 2006;296(19):2351&#8211;61.</td><td><a href=http://dx.doi.org/10.1001/jama.296.19.2351>10.1001/jama.296.19.2351</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR48_4</td><td>BibArticle</td><td>Kaufman JM, Graydon RJ. Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men. J Urol 2004;172(3):920&#8211;2.</td><td><a href=http://dx.doi.org/10.1097/01.ju.0000136269.10161.32>10.1097/01.ju.0000136269.10161.32</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR49_4</td><td>BibArticle</td><td>Agarwal PK, Oefelein MG. Testosterone replacement therapy after primary treatment for prostate cancer. J Urol 2005;173(2):533&#8211;6.</td><td><a href=http://dx.doi.org/10.1097/01.ju.0000143942.55896.64>10.1097/01.ju.0000143942.55896.64</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR50_4</td><td>BibArticle</td><td>Sarosdy MF. Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy. Cancer 2007;109(3):536&#8211;41.</td><td><a href=http://dx.doi.org/10.1002/cncr.22438>10.1002/cncr.22438</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr></table>